COO
Catalyst Pharmaceuticals, Inc.
Equibles does not estimate personal net worth.
Steven Miller is recorded as COO at Catalyst Pharmaceuticals, Inc.. The newest filing on record that lists Steven Miller as COO at Catalyst Pharmaceuticals, Inc. is dated April 11, 2025. Catalyst Pharmaceuticals, Inc. reported in an 8-K filed December 7, 2023 that Steven Miller was appointed Executive Vice President, Chief Operating and Scientific Officer, effective January 1, 2024. Steven Miller has spoken on 20 earnings calls across 1 company, most recently for Catalyst Pharmaceuticals, Inc. on September 30, 2025. Catalyst Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector.
“effective on January 1, 2024, Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer”
“With regard to the Markman hearing, it was relatively routine. There were a number of items that were simply pushed off to trial. The judge said simply that's a matter for trial.”
“As we've previously announced, we expect, or as Rich described, we expect again — I'm sorry, FIRDAPSE to be launched in Japan at the end of the year.”
“Well, Samantha, as it's generally bad practice to comment on ongoing litigation. I can tell you that we are working diligently to bring the cases to a favorable conclusion for Catalyst.”
“As Rich noted, our performance during the first quarter of 2024 has set us on pace for another strong year driven by our solid financial performance, financial discipline and strong execution.”
“I would first like to discuss our development efforts to increase the indicated maximum dose of FIRDAPSE.”
Catalyst Pharmaceuticals, Inc.
COO
Proxy statement
Start not stated–present
Last confirmed April 11, 2025
Catalyst Pharmaceuticals, Inc.
Biotechnology · Healthcare
COO
Catalyst Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Catalyst Pharmaceuticals, Inc.
